of thrombosis and whether DAPT should be individualized according to stent type or lesion or patient subsets is unknown. The Patient Related Outcomes with Endeavor versus Cypher Stenting Trial (PROTECT) was designed and powered to compare long-term outcomes of safety endpoints such as ST between the Endeavor zotarolimus-eluting stent (E-ZES) and the Cypher sirolimus-eluting stent (C-SES). Methods: PROTECT is a prospective, multicenter, randomized trial conducted at 196 sites in 36 countries worldwide in all continents. Patients with up to 4 coronary lesions amenable for stenting were randomized to receive E-ZES or C-SES. The primary endpoint is the 3 year rate of ARC-defined definite and probable ST. DAPT with clopidogrel and aspirin were prescribed at least for 3 months and at physician discretion for 12 months or longer. Planned and actual duration of DAPT, utilization of aspirin (ASA) and clopidogrel by region, and aspirin dose (Ͻ100mg, 100-300 mg, Ͼ300mg) were collected. Multivariate regression analysis will be used to identify predictors for DAPT duration of Ն12 months, DAPT compliance, and the relationship of these factors with the outcomes of ST, myocardial infarction and cardiac death. Results: PROTECT enrolled 8,800 patients; mean age 62.2Ϯ10.6 years and 76.3% were male. Overall, 44.7% of patients presented with acute coronary syndromes, 27.2% had diabetes mellitus, 20.5% prior MI, and 12.5% prior PCI. Almost all were de novo lesions (98.2%), 46.6% in the left anterior descending artery and 54.8% were B2/C lesions. Details of DAPT usage (planned and actual duration, ASA dosage) by region, and according to patient characteristics will be available for presentation. Conclusions: Analysis of the variation in duration of DAPT across regions and according to patient characteristics in a real world setting will further our understanding of the impact of DAPT on stent specific and global cardiovascular outcomes.
Background: Platelet activation plays a critical role in the pathogenesis of acute myocardial infarction (AMI). This study aimed to determine whether the results of platelet function assays used to measure response to clopidogrel therapy are similar among patients with stable CAD and those with AMI undergoing percutaneous coronary intervention (PCI) both at the index admission and at 30 days' post admission. Methods: Sixty patients were prospectively enrolled into either an elective PCI cohort or an AMI cohort. Patients presenting with an AMI were approached within 24 hours of presentation and following PCI for participation. Patients underwent platelet function testing post-PCI and again at 30 days (Ϯ 2 weeks) follow up. Tests included vasodilator stimulated phosphoprotein phosphorylation (VASP) and VerifyNow P2Y12. Results: The average age of the population was 64.5 Ϯ 11.2 years with no difference between the elective and AMI groups. Baseline characteristics were similar, with an overall rate of diabetes of 26.7%, hypertension 78.3%, current smokers 15.0%, prior CAD 35.0%, renal insufficiency 6.7% and the average BMI was 31 Ϯ 7. The AMI group had higher PRU, percent inhibition, and PRI at the time of PCI as compared to the elective PCI group. This difference was not sustained at 30 days. The PRU significantly decreased at 30 days compared to the PCI procedure for the AMI group. Similarly, the percent inhibition and PRI decreased, but did not achieve statistical significance. (Table) . Conclusions: Platelet reactivity is higher at the time of primary PCI (vs. elective PCI) with AMI presentation. These data support the notion that the platelets become hypersensitive at the time of AMI and are passivated over time given antiplatelet therapy. The on-treatment platelet reactivity should be assessed for patients presenting with AMI to appropriately tailor the antiplatelet regime. 
TCT-745
Can aspirin / clopidogrel resistance affect on the occurrence of intra-stent thrombi ?
as shown in the Background: Although high on-treatment platelet reactivity (HoTPR) predicts future ischemic events after percutaneous coronary intervention (PCI), the clinical applicability of platelet function testing remain unclear. This study aims to evaluate the impact of platelet function testing results on the managing physician's response to escalate antiplatelet therapy after PCI. Methods: The study included 465 consecutive patients undergoing PCI who were on Ն5 days of maintenance clopidogrel therapy. We performed platelet function testing with the Verify Now P2Y12 (Accumetrics) assay before the PCI. The result of this assay was made known to the managing physician after PCI. HoTPR was defined as Ͼ230 P2Y12 reaction units (PRU). Antiplatelet therapy at baseline and at hospital discharge post-PCI was recorded. We also evaluated the 30-day major adverse clinical events (MACE: all-cause mortality, myocardial infarction, and target vessel revascularization) in this population.
Results:
The mean age of the study population was 63 years; 73% were male and 22% were African-American. HoTPR was present in 143 patients (30.8%). Of these, only 21(14.7%) were managed with an escalation of antiplatelet therapy (increased clopidogrel dose or switched to prasugrel). Of the remaining 322 patients with appropriate platelet inhibition of Յ230PRU, 55 (17.1%) received more intensive antiplatelet therapy. Patients more likely to receive intensified antiplatelet therapy were those with a history of coronary artery bypass grafting (pϭ0.03), diabetes mellitus (pϭ0.03), and dialysis (pϭ0.04), as well as those presenting with myocardial infarction (pϭ0.014), receiving vein-graft PCI and treatment to a complex (ACC/AHA type C) lesion. At 30 days, 4 MACE events occurred. The group with HoTPR who received intensified antiplatelet therapy had the highest proportion of events (4.7% vs 2.2%, pϭ0.04).
Conclusions:
The results of platelet function testing do not significantly impact decisions to alter amtiplatelet therapy post-PCI. Rather, baseline clinical and angiographic parameters were primary factors considered when intensifying antiplatelet therapy. Background: ADP-specific platelet function assays were shown to predict thrombotic events, and might be helpful to select candidates for more potent antiplatelet therapy. We aimed to determine the efficacy and safety of giving intensified antiplatelet therapy on the basis of platelet reactivity testing for patients undergoing percutaneous coronary intervention (PCI). Methods: Electronic databases were searched to find prospective, randomized trials that reported the clinical impact of using an intensified antiplatelet protocol (repeated loading or elevated maintenance doses of clopidogrel, prasugrel or glycoprotein IIb/IIIa inhibitor) on the basis of ADP-specific platelet reactivity testing (using VerifyNow, Multiplate, VASP or light transmission aggregometry) compared to standard-dose clopidogrel. Evaluated efficacy measures included cardiovascular death, non-fatal myocardial infarction and definite/probable stent thrombosis (ST), while major bleeding events were recorded as safety endpoint. Results: Between 2008 and 2011, 10 clinical trials comprising 4,213 randomized patients were identified. Compared to standard antiplatelet therapy, the intensified protocol was associated with a significant reduction in cardiovascular mortality, ST and myocardial infarction (pϽ0.01 for all). There was no difference in the rate of major bleeding events between intensified and standard groups (Pϭ0.44). Although the observed effects regarding mortality, ST and bleeding were not heterogeneous, meta-regression analysis revealed that the net clinical benefit of the more potent antiplatelet strategy in patients with HPR significantly depended on the risk of ST of the control group using standard-dose clopidogrel (pϭ0.023).
TCT-747

Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis
Conclusions:
Intensifying antiplatelet therapy on the basis of platelet reactivity testing might reduce cardiovascular mortality and ST after PCI, without increasing major bleeding complications. However, the net benefit of giving more potent agents based on platelet function testing depends on the risk of ST with standard-dose clopidogrel. Background: The potential negative metabolic interaction between proton pump inhibitors (PPI) and clopidogrel is of particular concern. We have hypothesized that doubling the maintenance dose (MD) of clopidogrel (150mg, double) was less effective than switching to prasugrel 10mg MD (switch) to attenuate this potential negative interaction. Methods: In a prospective randomized placebo-controlled double blind study, we assigned 82 stable coronary artery disease patients treated with 75 mg clopidogrel MD dose and aspirin to receive lanzoprazole (30mg/day) or placebo in addition to either clopidogrel double MD (150 mg/jour) or standard prasugrel MD (10 mg/jour). The primary endpoint was the relative change in residual platelet reactivity (RPA, assessed by light transmission aggregometry, 20Mol ADP) over the 14 days study period [(RPAbaseline-RPA14day)/RPAbaseline]. All the measures were performed 4 hours after drug intake. Exclusion criteria were instability, contraindication to prasugrel and a mandatory use of PPI. Results: Baseline characteristics were balanced between the 4 groups. The effect of a double clopidogrel MD on RPA was significantly blunted by the co-administration of lansoprazole (-53.6Ϯ48.6% versus 0.8Ϯ53.7% without and with lansoprazole, respectively, pϽ0.001) whereas 10 mg of prasugrel MD dramatically reduced RPA irrespective of lanzoprazole co-administration (-81.8Ϯ24.8% versus -72.9Ϯ32.9%, without and with lanzoprazole, respectively, pϭNS). In patients receiving double clopidogrel MD and lansoprazole, RPA was not significantly different from that of clopidogrel 75mg MD alone. These findings were consistent irrespective of the platelet function test used to assess RPA. PPI use was the only parameter with a significant interaction with RPA among clopidogrel groups. CYP2C19 metabolizer status displayed non-significant interaction with RPA irrespective of the thienopyridine strategy.
TCT-748
Double The Dose Of Clopidogrel Or Switch To Prasugrel To Antagonize Proton Pump Inhibitor Interaction
Conclusions:
The effect of a double clopidogrel MD on platelet inhibition is significantly attenuated by the co-administration of lansoprazole as opposed to prasugrel 10mg. 
